https://www.selleckchem.com/pr....oducts/adenosine-dis
of therapeutic strategies aimed at restoring striatal ACh-DA imbalance in PD.Purpose of the study To report the safety evaluation of 177Lu-PSMA-617 derived from the cohort of 64 patients exposed to 177Lu-PSMA-617 in the RESIST-PC trial NCT03042312 Methods RESIST-PC was a prospective multicenter phase 2 trial. Patients with progressive mCRPC after ≥1 novel androgen-axis drug, either chemotherapy naïve or post-chemotherapy, with sufficient bone marrow reserve, normal kidney function, sufficient PSMA expression by P
Like
Comment
Share
